Paracetamol (Acetaminophen) Overdose

Meet the patient

A 19-year-old student is brought in two hours after swallowing a handful of paracetamol during an argument. She is tearful but clinically well, her abdomen is soft, and her liver function tests are normal; she asks to go home.[6][9]

Two exam questions are now live: is she safe to discharge, and what single test, drawn at what time, decides whether she gets the antidote? The danger is the well window — she looks and feels fine while NAPQI is already binding the hepatocyte proteins that will declare themselves two days later. Everything below exists to time the level, plot the nomogram, and give N-acetylcysteine before the eight-hour line.[1][7]

What paracetamol overdose is — and why the well-looking patient is the trap

Paracetamol (acetaminophen, N-acetyl-p-aminophenol) is the most widely used analgesic-antipyretic in the world. It is also the single most important poisoning to master for any medical exam and any clinical practice — it is common, potentially lethal, and, crucially, almost entirely preventable and treatable when N-acetylcysteine (NAC) is given early. Across the developed world it is the leading cause of acute liver failure (ALF), ahead of all other drug-induced and viral causes combined.[6]

The clinical skill in paracetamol overdose rests on six decisions, made in sequence: (1) take a precise time of ingestion (or recognise a staggered or unknown-time presentation); (2) draw a paracetamol level at 4 hours (never before — absorption is incomplete); (3) plot the level on the treatment nomogram and decide if it lies above the line; (4) start NAC immediately if above the line, or empirically if the nomogram does not apply (staggered, unknown time, modified-release, repeated supratherapeutic, or established hepatotoxicity); (5) monitor ALT, INR, creatinine, lactate, pH and glucose across the 24-to-72-hour window when hepatotoxicity declares itself; and (6) recognise King's College Criteria for urgent transplant referral.[1][4]

The signature trap of this overdose is its asymptomatic early phase: at 4 to 12 hours the patient looks and feels well, liver enzymes are normal, and yet NAPQI is already forming covalent adducts on hepatocyte proteins. Reassuring such a patient and discharging them without a 4-hour level is one of the classic and lethal pitfalls in clinical toxicology.[9]

Five ways the overdose happens — and which one breaks the nomogram

Paracetamol overdose is classified by the pattern of ingestion, because the pattern dictates whether the nomogram can be used and whether treatment is empirical.[6]

[7] [9] [6]

Two operational definitions anchor the topic. Hepatotoxicity is defined as an ALT above 1000 U/L following paracetamol exposure — the outcome definition used in comparative studies of NAC regimens. Paracetamol-induced acute liver failure is the patient with paracetamol hepatotoxicity who develops coagulopathy and encephalopathy — the variables (INR, conscious level) that drive validated outcome models. The treatment line on the nomogram is the single most important number in management: 150 mg/L at 4 h on the US Rumack-Matthew line, extended to 24 h with a paracetamol half-life of 4 h and subsequently adopted in Australia and New Zealand, or the single 100 mg/L line used in the UK since 2012.[13][6][19]

[6] [7]

How common, how lethal, and who is the high-risk host

Paracetamol overdose is among the commonest deliberate self-poisoning agents worldwide and is the single largest cause of acute liver failure in the United States, the United Kingdom, Europe, and Australasia.[6] In the United States Acute Liver Failure Study Group (ALFSG) registry, paracetamol accounts for roughly 46 percent of all adult ALF, and the majority are unintentional (supratherapeutic ingestions over days rather than single deliberate overdoses).[10] The United Kingdom records roughly 70,000 to 90,000 paracetamol overdoses per year, leading to roughly 200 to 300 deaths.[6]

The single most important population-level prevention intervention is the 1998 UK legislation limiting pack size for over-the-counter paracetamol sales; debate has continued ever since, and subsequent publications suggest the effects were small.[12] No comparable federal limit exists in the United States, where the contribution of unintentional supratherapeutic ingestion to ALF is correspondingly larger.

[14] [18]

The dose-response is steep but captured only imperfectly by the history. The 150 mg/kg estimated dose is widely considered the criterion for overdose; against the 150 mg/L treatment line it shows 92.6 percent sensitivity and 55.3 percent specificity, and in one retrospective series no patient with a dose estimate below 150 mg/kg developed hepatotoxicity. Reported dose alone should therefore never withhold treatment when the timed level or clinical picture suggests risk. Children remain relatively protected — serious toxicity after accidental paediatric ingestion is rare.[14][8]

Why the liver dies — saturation, NAPQI, and the zone-3 pattern

The molecular cascade of paracetamol toxicity is one of the best-elucidated in clinical toxicology, and it explains every aspect of the clinical syndrome — the early well window, the centrilobular necrosis, the 24-to-72-hour lag, and the mechanism of the antidote.[3]

At therapeutic doses paracetamol is metabolised in the liver along three routes, and the balance between them determines toxicity.[6]

1. Glucuronidation (about 40 to 67 percent) via UGT1A1 and UGT1A6 — produces an inactive, water-soluble glucuronide conjugate excreted renally.
2. Sulfation (about 20 to 46 percent) via SULT1A1, SULT1A3 and SULT1A4 — produces an inactive sulfate conjugate excreted renally.
3. A small oxidative fraction (about 5 to 10 percent) via CYP2E1 (with minor contributions from CYP1A2 and CYP3A4) — generates the reactive intermediate NAPQI (N-acetyl-p-benzoquinone imine).[6]

In health, every molecule of NAPQI is immediately conjugated with the sulfhydryl group of glutathione (GSH) to form a non-toxic mercapturic acid conjugate (cysteine and mercapturate) that is excreted in urine. The intracellular GSH pool is large enough that this minor oxidative fraction is harmless.[3]

In overdose, two things happen. First, sulfation saturates (it has a lower capacity than glucuronidation), then glucuronidation saturates, so a larger fraction of paracetamol is shunted through CYP2E1. NAPQI production rises sharply. Second, the GSH pool is consumed — hepatotoxicity ensues when hepatic GSH falls to under 30 percent of normal. Once GSH is depleted, free NAPQI binds covalently to cysteine residues of hepatocyte cellular proteins, forming NAPQI-protein adducts.[3]

The downstream cellular injury is mitochondrial: NAPQI-protein adducts damage mitochondrial proteins, open the mitochondrial permeability transition pore (mPTP), disrupt ATP synthesis and intracellular calcium homeostasis, and generate reactive oxygen and nitrogen species (superoxide, peroxynitrite). The result is mitochondrial dysfunction, hepatocyte oncotic (necrotic) and apoptotic cell death, amplified by a secondary inflammatory wave — Kupffer-cell activation, TNF-alpha, IL-1, and neutrophil recruitment.[10]

The injury is zonally restricted. CYP2E1 and the cytochrome P450 system are most concentrated in centrilobular (zone 3) hepatocytes (near the central vein), and zone 3 has the lowest oxygen tension in the liver acinus. The histological signature of paracetamol toxicity is therefore classical centrilobular (zone 3) coagulative necrosis, with sparing of the periportal (zone 1) hepatocytes — a pattern that explains both the extreme transaminase elevation (massive zone 3 cell death) and the eventual complete regeneration (zone 1 cells survive and repopulate).[5]

The renal mechanism parallels the hepatic one. Renal cortical cells express CYP2E1 and generate local NAPQI, producing acute tubular necrosis (ATN) in roughly 1 to 2 percent of overdoses. Notably, renal injury may occur without or before overt liver injury.[1]

[3]

The four phases — read the clock, not the patient

The clinical course of untreated paracetamol toxicity unfolds in four classical phases, each with its own diagnostic and prognostic weight. Knowing the phase by the clock is what allows the clinician to anticipate injury before it declares itself.[6]

Phase 1 (0 to 24 h) — the "well window". The patient is typically asymptomatic or has only mild nausea, vomiting, pallor, malaise, and diaphoresis. Liver enzymes, INR, and bilirubin are normal. The patient looks and feels well — and this is precisely the danger, because NAPQI is already forming hepatocyte adducts that will declare themselves 24 to 48 hours later. The single most dangerous management error at this phase is reassurance and discharge.[10]

Phase 2 (24 to 72 h) — hepatotoxicity declares itself. Right-upper-quadrant pain and tender hepatomegaly may appear. Aminotransferases rise — hepatotoxicity is conventionally defined as an ALT above 1000 U/L, and values can be far higher. Coagulation (INR/prothrombin time) worsens as synthetic function fails, and creatinine rises with kidney injury. This is the phase in which injury is occurring; the patient is no longer well.[13][7]

Phase 3 (72 to 96 h) — peak hepatotoxicity / acute liver failure. The full syndrome of ALF emerges: jaundice, coagulopathy, hypoglycaemia (impaired gluconeogenesis), metabolic (lactic) acidosis (impaired lactate clearance plus hypoperfusion), hepatic encephalopathy progressing from grade I (mild confusion, sleep disturbance) through grade II (drowsiness, disorientation) and grade III (somnolence but rousable, agitation) to grade IV (coma), cerebral oedema (Cushing's triad of hypertension, bradycardia, irregular respirations), renal failure, and multi-organ failure. Death is from cerebral oedema or sepsis.[10]

Phase 4 (4 days to 2 weeks) — recovery. In survivors, ALT, INR, and symptoms resolve over 1 to 2 weeks; complete histological recovery occurs over weeks to months WITHOUT cirrhosis — the liver regenerates fully because zone 1 hepatocytes are preserved.[10]

Atypical presentations

Examiners test atypical presentations deliberately. The elderly present non-specifically with comorbidity and polypharmacy; the pregnant patient has fetal risk and a lower threshold to treat; the chronic alcoholic or malnourished patient develops severe hepatotoxicity at low doses via RSI; the child presents after accidental ingestion and needs a level; the patient on enzyme inducers (rifampicin, phenytoin, isoniazid, antiretrovirals) is toxic at lower doses; and the staggered or unknown-time patient presents at 24 to 72 h already in phase 2 or 3 with no reliable early history.[6]

The anaphylactoid reaction to NAC

A separate clinical event is the anaphylactoid (non-IgE) reaction to intravenous NAC itself. In a large Canadian cohort treated with the 21-h IV protocol, a reaction was documented in 8.2 percent of 6455 courses; 75.4 percent were cutaneous (urticaria, pruritus, angioedema) and 95.4 percent occurred within the first 5 hours — that is, around the loading infusion. Higher serum paracetamol concentrations are associated with fewer reactions, and a Danish cohort found the two-bag regimen, antihistamine pre-treatment and high plasma paracetamol each associated with a lower incidence. Antihistamines were the drugs given in 92 percent of treated reactions. NAC should not be abandoned — none of these associations is strong enough to substantially alter the threshold for NAC initiation.[20][21]

The mimics — and the discriminator that ends each

Acute liver failure from paracetamol is a well-characterised syndrome described in prospective multicentre cohorts, but when the history is uncertain, an acute hepatitis picture with coagulopathy and encephalopathy has a broad differential in which the following must be distinguished.[10][13]

Two intra-paracetamol distinctions matter for management. Single acute ingestion (nomogram valid) must be distinguished from staggered ingestion (nomogram invalid, treat empirically) and from repeated supratherapeutic ingestion (use the RSI pathway, not the standard nomogram).[6][7]

The history is the investigation — nine things to pin down

The history is the single most important step in paracetamol overdose, and it must be precise. Establish: (1) the exact time of ingestion (to the hour — the nomogram depends on it); (2) the total dose in mg (and mg/kg, dividing by body weight); (3) the formulation (immediate release versus modified release); (4) whether single or staggered (over more than 1 to 2 hours); (5) co-ingestants (alcohol, salicylate, opioid, TCA, toxic alcohol); (6) regular medications (especially enzyme inducers); (7) alcohol and fasting history; (8) intent (deliberate self-harm versus accidental); and (9) the patient's weight.[6]

The focused bedside examination follows ABCDE: Airway (patency, especially with a co-ingested sedative); Breathing (rate, SpO2 — risk of aspiration); Circulation (HR, BP, capillary refill — hypotension suggests late ALF or co-ingestant); Disability (GCS — normal early; coma suggests co-ingestant or late cerebral oedema); and Exposure (stigmata of chronic liver disease, jaundice at 24 to 72 h, needle marks, evidence of self-harm).[6]

A bedside capillary glucose must be checked in every paracetamol overdose — hypoglycaemia at any phase is a red flag for hepatic failure. Mental-state and suicide-risk assessment is mandatory; no deliberate-self-harm patient should be left unattended, and psychiatric assessment is required once the patient is medically stable.[5]

The early-phase examination is typically normal — and this is the trap. At 0 to 24 h there may be nausea, vomiting, pallor and diaphoresis but no hepatomegaly, no jaundice, no encephalopathy. At 24 to 72 h, right-upper-quadrant tenderness, hepatomegaly, jaundice and dark urine appear. At 72 to 96 h the picture of ALF is unmistakable: encephalopathy, asterixis (liver flap), fetor hepaticus, and signs of cerebral oedema (Cushing's triad).[4]

The 4-hour level, the nomogram, and when both are useless

The essential blood panel in every paracetamol overdose is: serum paracetamol level (timing critical), U&E (sodium, potassium, creatinine), LFTs (ALT, AST, bilirubin, albumin), coagulation (INR/PT), venous or arterial blood gas (pH, lactate, bicarbonate), capillary glucose, FBC, and a salicylate level (to exclude co-ingestion). Group and Save if INR is elevated.[6]

[6]

The paracetamol level — timing is everything

The serum paracetamol level must be drawn at 4 hours (or later) after a single acute ingestion. Levels drawn before 4 h are uninterpretable because absorption is incomplete. The level can be plotted on the nomogram from 4 to 24 hours post-ingestion.[1]

The treatment nomogram

Plot serum paracetamol (y-axis, log scale) against hours post-ingestion (x-axis, linear). Above the treatment line = treat with NAC. The treatment lines are:[6]

• US Rumack-Matthew treatment line: 150 mg/L at 4 h, extended to 24 h with a paracetamol half-life of 4 h — the line used by the US National Multicenter Study, now standard in the US and subsequently adopted in Australia and New Zealand.[6][14]
• UK line: the UK initially used the higher Rumack-Matthew risk line; in September 2012 the MHRA lowered the treatment line to a single 100 mg/L at 4 h for all patients — a lower threshold than that used in the United States, Canada, Australia and New Zealand.[6][23]

The line is a straight extrapolation assuming a paracetamol half-life of 4 h. Below the line = no NAC (provided the timing is correct and the patient is well).[6]

When the nomogram CANNOT be used

The nomogram is invalid in:[6]

1. Staggered ingestion (doses over more than 1 to 2 h).
2. Unknown time of ingestion.
3. Modified-release paracetamol.
4. Repeated supratherapeutic ingestion.
5. Presentation more than 24 h post-ingestion (the nomogram stops at 24 h).
6. The patient already has established hepatotoxicity.[9]

In all of these situations, treat empirically with NAC — do not wait for a level or a nomogram decision.[6]

King's College Criteria (KCC) — for paracetamol-induced ALF

The King's College Criteria (O'Grady 1989) identify patients with paracetamol-induced ALF who have over 80 percent mortality without transplant and require urgent transplant referral.[4]

[19]

Laboratory hallmarks of established hepatotoxicity

• ALT/AST markedly raised — hepatotoxicity is conventionally defined as an ALT above 1000 U/L, and values can be far higher.
• Coagulation (INR/prothrombin time) and creatinine — central prognostic variables, together with arterial pH and lactate, in validated outcome models.
• Hyperbilirubinaemia, hypoglycaemia, acidosis and acute kidney injury accompany established injury.[13][19]

The combination of a marked aminotransferase rise with coagulopathy in the right clinical context constitutes the working diagnosis of paracetamol hepatotoxicity.[13]

Monitoring schedule

For an admitted patient: ALT, INR, creatinine, venous lactate, venous pH at baseline then every 12 to 24 hours (more frequently if any abnormal); continuous cardiac monitoring during the NAC loading dose; capillary glucose every 1 to 2 h if hypoglycaemic. A low or undetectable paracetamol level in late or staggered ingestion does not exclude toxicity.[6][19]

Additional investigations as indicated: salicylate level, ethanol level, toxic alcohol screen (if osmolar gap), pregnancy test, viral hepatitis serology (if differential uncertain), and — at specialist centres — the paracetamol-cysteine adduct assay (a specific biomarker of paracetamol exposure when timing is unclear).[10][6]

The first hour — charcoal, glucose, and the decision to start NAC

The time-critical resuscitation bundle for any significant paracetamol overdose is:[15]

1. ABCDE assessment, IV access, and baseline bloods — a timed paracetamol concentration plus the laboratory and monitoring parameters set out in recent North American consensus guidance.
2. Do not be reassured by an asymptomatic patient in the well window.
3. Treat hypoglycaemia with intravenous dextrose.
4. Correct hypovolaemia with crystalloid; treat hypotension as a marker of severe injury or co-ingestant.
5. Identify co-ingestants — the consensus statement specifically addresses coingestion of anticholinergics or opioids.[15]

GI decontamination

Single-dose activated charcoal reduces absorption, but its effectiveness decreases with time: volunteer data using at least 50 g showed mean reductions in absorption of 47.3 percent at 30 minutes, 40.1 percent at 60 minutes, and 16.5 percent at 120 minutes after dosing. Patients who present early should be given activated charcoal.[22][7] Activated charcoal is an adjunct to NAC, not a substitute. The pivotal early decision is whether the patient needs NAC at all, and that decision should be made within 8 hours of ingestion to maximise efficacy.[2]

Indications for immediate empirical NAC (do not wait for level/nomogram)

[7] [14]

Resuscitation of established ALF

If the patient presents in established ALF, follow standard liver-failure protocols: supportive critical care, management of cerebral oedema and coagulopathy per transplant-unit protocols, treatment of sepsis, intubation for advanced encephalopathy, and urgent transplant referral if poor-prognosis criteria are met. Keays 1991 showed that conventional intensive liver care alone carried a 20 percent survival versus 48 percent with continued NAC in paracetamol-induced fulminant hepatic failure.[4][5]

There is no established role for any antidote beyond NAC in standard paracetamol overdose; adjuncts such as fomepizole and extracorporeal elimination are specifically addressed — as open questions — in recent North American consensus guidance for high-risk ingestions.[15]

N-acetylcysteine — the 150-50-100 regimen, and when to keep going

The IV NAC 21-hour three-bag regimen

The three-bag regimen — 150 mg/kg over 1 h, 50 mg/kg over 4 h, 100 mg/kg over 16 h — derives from the intravenous regimens introduced in the UK and subsequently in the US, and remained effectively unchanged from the 1970s until recently.[6][13]

[13] [6]

In children, the diluent volumes must be reduced (use a more concentrated NAC preparation) to avoid fluid overload and hyponatraemia, especially in those under 20 kg or under 5 years.[7]

The same weight-related dose of NAC is used irrespective of the paracetamol dose, and newer regimens give the loading dose more slowly to reduce adverse reactions. The SNAP-modified UK regimen (100 mg/kg over 2 h followed by 200 mg/kg over 10 h) has been widely adopted in the UK with comparable efficacy; the ANZ two-bag regimen (200 mg/kg over 4 h then 100 mg/kg over 16 h) has similar efficacy to the three-bag regimen with significantly fewer adverse reactions; and a 12-h two-bag variant delivering the same 300 mg/kg total was trialled against the standard 20.25-h course in the SNAP study.[16][6][7][13]

When to continue NAC beyond 21 hours

When continuing beyond the standard course, repeat bloods at the end of treatment and at regular intervals — repeating blood tests at the end of acetylcysteine treatment identifies the small proportion of patients who develop liver injury despite early treatment and indicates those requiring continuation. Continue while aminotransferases are rising, coagulation remains abnormal, or paracetamol remains detectable.[13][15]

The oral NAC regimen (where IV unavailable)

Loading 140 mg/kg, then 70 mg/kg every 4 hours for 17 doses over 72 hours. On the basis of the US multicenter data, the 72-hour oral regimen was as effective as the 20-hour intravenous regimen. Nausea and vomiting are frequent with oral NAC — ondansetron pre-treatment was specifically studied in the SNAP trial.[2][16]

Managing the NAC anaphylactoid reaction

Most reactions are mild and cutaneous and cluster around the loading infusion.[20]

• Pause or slow the infusion — reactions are predominantly cutaneous (urticaria, pruritus, angioedema).
• Antihistamines are the standard treatment (given in 92 percent of treated reactions in a national cohort), and antihistamine pre-treatment is associated with a lower incidence.
• Resume the infusion once symptoms settle; do not let the reaction delay completion.
• For reactions with hypotension or respiratory symptoms, treat supportively and involve critical care.
• Do NOT abandon NAC — its life-saving benefit outweighs the reaction risk.[20][21]

Premedication is not routinely recommended but may be considered in patients with a history of reaction, asthma, or atopy.[7]

Scenario-specific management

[7] [17] [18] [4]

King's College Criteria met — what to do

Once KCC are met, urgent transplant centre referral is time-critical (the window is short).[4]

• Continue NAC — it remains beneficial even in established ALF (Keays 1991 showed improved survival in established ALF).[5]
• Manage cerebral oedema and coagulopathy per transplant-unit protocols.
• Treat sepsis — paracetamol ALF patients are functionally immunosuppressed; surveillance cultures and a low threshold for antibiotics.
• Do NOT correct the INR with FFP or vitamin K before transplant assessment — this confounds the prognostic INR, which is the key KCC variable. Correct coagulopathy only if actively bleeding or before an invasive procedure.[4]

De-escalation and discharge

Discharge only when: NAC course complete, ALT and INR falling, INR under 1.3, clinically well, psychiatric assessment completed (for deliberate self-harm), and a safety plan in place. Counsel the patient that hepatic recovery is complete and there is no chronic liver damage.[6][13]

Psychiatric assessment is mandatory before discharge in all deliberate self-harm overdoses — in many jurisdictions it is a medico-legal requirement.[1]

Scenarios you will actually meet

Acute single ingestion in a healthy adult

Take a precise time, give charcoal early if presenting within the first hour, draw a level at 4 h, plot on the nomogram, give NAC if above the line. When given within 8 h of ingestion, NAC was protective regardless of the initial plasma paracetamol concentration.[1][2][22]

Staggered overdose

The nomogram is invalid. Give NAC empirically. Admit and monitor ALT/INR. Optimal acetylcysteine dosing after staggered ingestion remains an acknowledged area of uncertainty.[6][7]

Modified-release paracetamol

Delayed absorption produces lower and later peak concentrations than immediate release and can confound the nomogram by underestimating severity early. All potentially toxic MR ingestions (at least 10 g or 200 mg/kg, whichever is less) should receive a full NAC course; ingestions of at least 30 g or 500 mg/kg should receive increased doses.[9][7]

Repeated supratherapeutic ingestion

Management differs from the standard nomogram approach: treatment decisions weigh a detectable paracetamol concentration against evidence of hepatic injury, and the precipitant should be identified and addressed.[7]

Pregnancy

Paracetamol crosses the placenta; the fetus is at risk. Do not delay assessment or treatment — recent North American consensus guidance sets specific treatment considerations for pregnancy.[15]

Children

Accidental paediatric ingestions are rarely toxic, but a level should still be checked. Intentional/adolescent deliberate self-harm is managed as for adults, with weight-based NAC dosing; specific guidance exists for children under 6 years. Continuous monitoring, and child-protection assessment for any suspicious or repeated presentation.[8][15]

Chronic alcoholic and malnourished/starved

Chronic alcohol use is often cited as increasing risk at lower doses, but the original US multicenter experience found no consistent difference in hepatotoxicity between patients with and without a history of chronic alcohol use, while acute alcohol co-ingestion was associated with less severe toxic reactions. Treat suspected risk empirically rather than relying on dose history.[1]

Patient on enzyme-inducing drugs

Rifampicin, phenytoin, carbamazepine, phenobarbital, isoniazid, efavirenz, nevirapine, St John's wort, zidovudine. Lower threshold to treat; consider the lower treatment line. NAC dosing unchanged.[7]

Established ALF / King's College Criteria met

Urgent transplant referral, transfer to a liver unit, continue NAC, manage cerebral oedema, coagulopathy, hypoglycaemia, renal failure, and sepsis.[4][5]

Mixed overdose

Paracetamol plus salicylate has a higher mortality than either alone. Paracetamol plus ethanol — chronic ethanol potentiates toxicity (CYP2E1 induction) but acute ethanol co-ingestion may transiently protect (competitive CYP2E1 inhibition). Treat each component.[6]

How the patient comes to harm — the preventable list

Disease complications

Classical pitfalls

Cerebral oedema of ALF

Increased intracranial pressure, Cushing's triad (hypertension, bradycardia, irregular respirations), pupillary changes, loss of brainstem reflexes. Cerebral oedema was significantly less frequent with continued NAC in the King's controlled trial (40 versus 68 percent). Management follows standard transplant-unit protocols, and urgent transplant assessment is the definitive treatment for patients meeting poor-prognosis criteria.[5][4]

Coagulopathy

Paracetamol-induced coagulopathy is a synthetic defect (impaired hepatic factor production), not a consumptive defect. INR is the most sensitive prognostic marker. Do NOT correct with FFP unless actively bleeding or before a procedure. Recombinant activated factor VII has been used before procedures.[4]

NAC anaphylactoid reaction

Reactions are predominantly mild and cutaneous and cluster in the first hours of infusion. Higher paracetamol concentrations are associated with fewer reactions, the two-bag regimen and antihistamine pre-treatment lower the incidence, and antihistamines are the standard treatment. Managed as above.[20][21]

Medicolegal pitfall

Deliberate self-harm overdoses require a formal psychiatric assessment and, in many jurisdictions, mandatory psychosocial assessment. Preserve the bottle/container and document the history.[6]

Prognosis turns on the clock — eight hours decides most of it

The prognosis of paracetamol overdose is excellent when NAC is given within 8 h of a single acute ingestion: Prescott's original IV series found virtually complete protection against liver damage in the 40 patients treated within eight hours, and Smilkstein's multicenter analysis found NAC protective regardless of the initial plasma concentration when given within eight hours.[3][2]

Prognosis worsens with later presentation: hepatotoxicity developed in 6.1 percent of at-risk patients when oral NAC was started within 10 h, in 26.4 percent when started at 10 to 24 h, and in 41 percent of high-risk patients treated at 16 to 24 h. But NAC remains beneficial even after hepatotoxicity has developed — Keays 1991 showed improved survival (48 percent versus 20 percent) when NAC was given in established paracetamol-induced fulminant hepatic failure.[2][5]

Established paracetamol ALF meeting King's College Criteria has a mortality over 80 percent without transplant; emergency liver transplantation reduces this to under 30 percent one-year mortality.[4]

Predictors of poor outcome

In acetaminophen-induced fulminant hepatic failure, survival correlated with arterial blood pH, peak prothrombin time and serum creatinine — a pH under 7.30, prothrombin time over 100 s and creatinine over 300 micromol/L indicating a poor prognosis. Modern validated models additionally weigh age, conscious level, arterial lactate, INR and cardiovascular failure on admission.[4][19]

Disposition

[15] [4] [19]

Safety-net on discharge

Complete hepatic recovery is the rule — no cirrhosis. Advise about the dangers of further paracetamol use. Safety plan and crisis numbers for deliberate self-harm patients. The high-risk patient (alcoholic, on enzyme inducers, eating disorder) should be advised to limit or avoid paracetamol. All deliberate self-harm cases require documented psychiatric follow-up and risk assessment before discharge.[6]

Special populations — pregnancy, children, the alcoholic, the anticoagulated

[15] [8]

Evidence and the names that score marks

The evidence base

The Rumack 1981 paper (Archives of Internal Medicine, 662 cases with oral acetylcysteine) is the foundation of the modern nomogram: patients at risk on the basis of their acetaminophen blood levels plotted on the study nomogram were treated with oral acetylcysteine, and 7 percent of those treated within ten hours showed transient transaminase elevations, versus 29 percent treated at ten to 16 hours and 62 percent treated at 16 to 24 hours. No deaths occurred among patients treated within 24 hours of ingestion.[1]

The Smilkstein 1988 NEJM study of oral NAC in 2542 patients established that hepatotoxicity developed in 6.1 percent of at-risk patients when NAC was started within 10 hours and in 26.4 percent at 10 to 24 hours, that NAC was protective regardless of the initial plasma concentration when given within 8 hours, and that the 72-hour oral regimen was as effective as the 20-hour intravenous regimen.[2]

The Prescott 1979 BMJ paper introduced intravenous NAC as "the treatment of choice" for paracetamol poisoning — virtually complete protection within 8 h (mean maximum ALT 27 IU/L in those treated within 8 h), with only 1 of 62 patients treated within 10 hours developing severe liver damage compared with 33 of 57 (58 percent) given supportive care alone.[3]

The Keays 1991 BMJ randomised controlled trial of IV NAC in paracetamol-induced fulminant hepatic failure (50 patients, established ALF) showed improved survival (48 percent versus 20 percent), less cerebral oedema (40 versus 68 percent) and less hypotension requiring inotropes (48 versus 80 percent) even when NAC was given AFTER hepatotoxicity had developed — this is why NAC is continued (or started) in established ALF.[5]

The O'Grady 1989 Gastroenterology paper (King's College) derived the King's College Criteria for paracetamol-induced ALF transplant referral — in acetaminophen-induced fulminant hepatic failure, survival correlated with arterial blood pH, peak prothrombin time and serum creatinine: pH under 7.30, prothrombin time over 100 s and creatinine over 300 micromol/L indicating poor prognosis.[4]

Regional deltas

Controversies

The 150 mg/L versus 100 mg/L treatment-line trade-off is well illustrated by the UK experience: lowering the line to 100 mg/L increased admissions and antidote use, and most additional treatments occurred in the 100 to 149 mg/L band — a group at low risk of hepatotoxicity and higher risk of adverse reactions.[23]

The optimal NAC regimen remains debated: the 21-h three-bag course, the ANZ two-bag (200 mg/kg over 4 h then 100 mg/kg over 16 h), the 12-h two-bag variant delivering 300 mg/kg, and the SNAP-modified UK regimen (100 mg/kg over 2 h then 200 mg/kg over 10 h) all deliver 300 mg/kg in total. No placebo-controlled or dose-ranging studies exist, and uncertainty persists about the optimal dose after very large overdoses. The two-bag ANZ regimen has similar efficacy with significantly fewer adverse reactions than the three-bag regimen.[13][16][7][6]

The paracetamol-cysteine adduct assay is an increasingly used specific biomarker of paracetamol exposure at specialist centres when timing/history is unclear, and biomarker development for early risk assessment is an active field.[10][6]

The mantra, and the memory devices

The mantra: time the ingestion, draw the level at four hours, plot the nomogram, and give NAC inside eight hours — the well patient is the one about to get sick.[1][2]

[16] [6] [3] [13] [4] [15] [6] [2] [13] [4]

Ward-round test — three stems, a minute each

Stem 1 — she took the tablets over a whole evening (answer)

The student from the vignette eventually admits she took eight tablets at 6 pm and another twelve at 10 pm and midnight. Can you use the nomogram, and what do you do? Model: No. A staggered overdose invalidates the nomogram — the nomogram is used only for acute immediate-release ingestions with a known time, and modified-release, massive and repeated supratherapeutic ingestions all require different management. Start the full intravenous N-acetylcysteine course empirically — 150 mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (or your local two-bag variant) — and monitor liver function, coagulation and renal function, repeating bloods at the end of treatment to identify any need for continuation. Optimal dosing in staggered ingestion remains an area of uncertainty.[7][13]

Stem 2 — the INR is climbing at 48 hours (answer)

A patient treated with NAC for a single large ingestion has right-upper-quadrant pain at 48 hours; ALT is 4000 and INR has risen from 1.1 to 2.6. The repeat paracetamol level is now below the treatment line. Stop the NAC? Model: No. The nomogram is irrelevant once hepatotoxicity has declared itself. Continue NAC — repeating blood tests at the end of treatment identifies the patients who need continuation (rising aminotransferases, persistent coagulopathy or still-detectable paracetamol). Now actively look for the King's College Criteria (arterial pH under 7.3 after fluids, or prothrombin time over 100 s with creatinine over 300 and grade III or IV encephalopathy); if met, refer for urgent transplant and do not correct the INR with fresh-frozen plasma first, because the coagulation status is the key prognostic variable.[13][4]

Stem 3 — she arrives at 3 hours and wants the level now (answer)

Three hours after a single ingestion of roughly 20 g, the patient demands a paracetamol level so she can be cleared. Do you draw it to decide treatment? Model: Not to decide treatment. Consensus defines the acute assessment window as 4 to 24 hours after overdose — earlier levels are uninterpretable because absorption is incomplete, so the decision level is drawn at 4 hours. If a timely level cannot be obtained, the 150 mg/kg dose-estimate is a satisfactory stand-alone criterion for starting NAC where levels are unavailable. Activated charcoal works best given early — volunteer data show its effect falls steeply after the first hour (47.3 percent reduction in absorption at 30 minutes, 40.1 percent at 60 minutes, 16.5 percent at 2 hours) — so never let charcoal or a premature level delay the eight-hour NAC window.[15][14][22]

References

1. [1]Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Archives of Internal Medicine, 1981.PMID 7469629
2. [2]Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine, 1988.PMID 3059186
3. [3]Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. British Medical Journal, 1979.PMID 519312
4. [4]O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology, 1989.PMID 2490426
5. [5]Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ, 1991.PMID 1954453
6. [6]Bateman DN, Dart RC, Dear JW, et al. Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973-2023 with particular focus on contributions published from Edinburgh and Denver. Clinical toxicology (Philadelphia, Pa.), 2023.PMID 38197864
7. [7]Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia, 2020.PMID 31786822
8. [8]Peterson RG, Rumack BH. Age as a variable in acetaminophen overdose. Archives of Internal Medicine, 1981.PMID 7469631
9. [9]Spyker DA, Dart RC, Yip L, Reynolds K, Brittain S, Yarema M. Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations. Clinical Toxicology (Philadelphia), 2022.PMID 36106921
10. [10]MacDonald AJ, Speiser JL, Ganger DR, Nilles KM, Orandi BJ, Larson AM, Lee WM, Karvellas CJ. Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study. Clinical Gastroenterology and Hepatology, 2021.PMID 32920216
11. [11]Chiew AL, Fountain JS, Graudins A, Isbister GK, Reith D, Buckley NA. Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia, 2015.PMID 26852051
12. [12]Bateman DN. Pack size and paracetamol overdose: 16 years later. Clinical Toxicology (Philadelphia), 2014.PMID 25200452
13. [13]Syafira N, Graudins A, Yarema M, Wong A. Comparing development of liver injury using the two versus three bag acetylcysteine regimen despite early treatment in paracetamol overdose. Clinical Toxicology (Philadelphia), 2022.PMID 34758680
14. [14]Chomchai S, Mekavuthikul P, Phuditshinnapatra J, Chomchai C. Sensitivity of dose-estimations for acute acetaminophen overdose in predicting hepatotoxicity risk using the Rumack-Matthew Nomogram. Pharmacology Research and Perspectives, 2022.PMID 35106928
15. [15]Dart RC, Mullins ME, Matoushek T, et al. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Network Open, 2023.PMID 37552484
16. [16]Thanacoody HK, Gray A, Dear JW, et al. Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP). BMC Pharmacology and Toxicology, 2013.PMID 23556549
17. [17]Hendrickson RG. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? Clinical Toxicology (Philadelphia), 2019.PMID 30777470
18. [18]Marks DJB, Dargan PI, Archer JRH, Davies CL, Dines AM, Wood DM, Greene SL. Outcomes from massive paracetamol overdose: a retrospective observational study. British Journal of Clinical Pharmacology, 2017.PMID 28002875
19. [19]Bernal W, Wang Y, Maggs J, et al. Development and validation of a dynamic outcome prediction model for paracetamol-induced acute liver failure: a cohort study. Lancet Gastroenterology and Hepatology, 2016.PMID 28404094
20. [20]Yarema M, Chopra P, Sivilotti MLA, et al. Anaphylactoid Reactions to Intravenous N-Acetylcysteine during Treatment for Acetaminophen Poisoning. Journal of Medical Toxicology, 2018.PMID 29423816
21. [21]Daoud A, Dalhoff KP, Christensen MB, Bogevig S, Petersen TS. Two-bag intravenous N-acetylcysteine, antihistamine pretreatment and high plasma paracetamol levels are associated with a lower incidence of anaphylactoid reactions to N-acetylcysteine. Clinical Toxicology (Philadelphia), 2020.PMID 31601129
22. [22]Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: Single-dose activated charcoal. Clinical Toxicology (Philadelphia), 2005.PMID 15822758
23. [23]Bateman DN, Dear JW, Carroll R, et al. Impact of reducing the threshold for acetylcysteine treatment in acute paracetamol poisoning: the recent United Kingdom experience. Clinical Toxicology (Philadelphia), 2014.PMID 25200454